Morgan Joseph Starts PROLOR Biotech (PBTH) at Buy; Breaking Into Biobetters & Biosimilars

Morgan Joseph initiates coverage on PROLOR Biotech (NYSE: PBTH) with a Buy. PT $16.

Morgan analyst says, "PROLOR is an emerging biotechnology firm with a specific focus on developing "biobetters" and "biosimilars"; these are classified as new forms of existing approved drugs. The firm possesses a core platform technology that permits the creation of altered versions of existing biologic agents (namely, protein macromolecules) with improved pharmacokinetics, thereby enhancing their delivery, dosing convenience, safety and efficacy. In our view, PROLOR represents a diversified and more risk-mitigated investment opportunity in the smallcap biotechnology sector."

For more ratings news on PROLOR Biotech click here and for the rating history of PROLOR Biotech click here.

Shares of PROLOR Biotech closed at $4.94 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
• Lake Street Starts RF Industries Ltd. (RFIL) at Buy
• JPMorgan Resumes SanDisk (SNDK) at Overweight